While audits are part of doing business in the ordinary course, businesses are generally less than eager to open the books. And the same is true when it comes to the 340B Drug Pricing Program. Audits ...

On April 28, AEI’s Kirsten Axelsen hosted the former North Carolina Department of Health and Human Services Secretary Kody Kinsley; Anthony DiGiorgio of the University of California, San Francisco; ...

In 2021, we provided an overview of multiple federal lawsuits challenging the US Department of Health and Human Services (HHS) Health Resources and Services Administration’s (HRSA) enforcement of the ...

Three judges for the U.S. Court of Appeals for the Washington, D.C. Circuit ruled May 21 in favor of drug manufacturers’ ability to limit sales and distribution of discounted drugs in the government’s ...

Johnson & Johnson has decided to terminate implementation of its 340B rebate plan, according to an internal email 340B Health shared with Becker’s. In late August, the drugmaker planned to replace ...

The Trump administration is pushing significant changes to the healthcare status quo that it says will save money, improve oversight and make the $4.9 trillion sector more efficient. Many of the HHS’ ...

In a letter last week, Johnson & Johnson informed certain hospitals of a major change it plans to make in the way it gives out discounts on two drugs. The company has found itself in opposition to ...

Drugmaker Johnson and Johnson is suing the Department of Health and Human Services and the Health Resources and Services Administration for blocking its new 340B rebate model, and is seeking to verify ...

The 340B program's expansion has shifted benefits to wealthier areas, increasing hospital market power and profit margins. Hospitals leverage 340B discounts to drive out competitors, enhancing their ...

The 340B Drug Pricing Program was designed to help safety net providers serve low-income patients, but it has since ballooned into a multibillion-dollar system dominated by large health systems — with ...

The drugmaker has joined Johnson & Johnson and Eli Lilly in filing suit against the Biden administration over controversial reform to the drug discount program. The 340B program was created more than ...

The rapid expansion of the federal 340B drug pricing program is significantly affecting Medicaid budgets, particularly in states where managed care plans oversee prescription drug benefits. New ...